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Background: Smoking worsens underlying asthma inflammation and also induces 
resistance to inhaled corticosteroids (ICS). Small airways dysfunction measured by 
impulse oscillometry (IOS) is associated with worse control.
Objectives: We investigated the effects on small airways of adding long-acting beta-
agonist (LABA) alone or with long-acting muscarinic antagonist (LAMA) to ICS in 
asthmatic smokers.
Methods: Sixteen current smokers were enrolled: mean age 44 year, FEV1 84%, 
FEF25-75 47%, R5 158%, ACQ 1.69, 20 pack year . Patients were converted to a 
reference ICS as HFA-BDP during initial run-in at median dose of 800 µg/day. Open 
label olodaterol 5 µg od (OLO) or olodaterol 5 µg/tiotropium 5 µg od (OLO/TIO) was 
added to HFA-BDP for median duration of 3 weeks in a randomized cross over de-
sign, including run-in and washout periods on HFA-BDP. IOS and spirometry were 
measured after each treatment (BDP/OLO/TIO or BDP/OLO) and at baseline after 
run-in and washout (BDP).
Results: After chronic dosing, IOS outcomes at trough except for R20 were all signifi-
cantly improved with OLO/TIO compared to OLO. For the primary end-point of total 
airway resistance (as R5), the mean difference (95%CI) at trough was 0.06 (0.015-
0.10) kPa/l/s, peripheral airways resistance (as R5-R20) 0.03 (0.003-0.06) kPa/l/s, 
peripheral lung reactance area (as AX) 0.38 (0.08-0.68) kPa/l and resonant frequency 
(as RF) 2.28 (0.45-4.12) Hz. FEF25-75 at trough was also better with OLO/TIO vs 
TIO: 0.93 (0.86 - 0.95) l/s while FEV1 was not different.
Conclusions: ICS/LABA/LAMA was superior to ICS/LABA on trough small airway 
outcomes in asthma patients who smoke.
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1  | INTRODUC TION
Patients with asthma who smoke represent a difficult challenge for 
clinicians. The smoking asthmatic may be considered as a separate 
phenotype in view of the inherent problems with clinical manage-
ment.1 The occurrence of smoking among asthma patients is higher 
among those with poor control and also in relation to socioeco-
nomic deprivation, with estimated prevalence rates of up to 20%.2-4 
Smoking worsens asthmatic inflammation, aggravates airway hy-
per-responsiveness and induces resistance to inhaled corticosteroid 
(ICS).5-8 Pointedly, most randomized controlled trials exclude asthma 
patients who smoke, hence there are a paucity of data in order to 
provide evidenced based guidelines for this phenotype.
The small airways are often overlooked when considering 
asthma management.9 This is perhaps surprising since the largest 
mucosal surface area of asthma inflammation is located in the dis-
tal airways. Indeed small airways dysfunction is common among all 
asthma severities.10,11 Hence, strategies to target the small airways 
are important in order to achieve optimal outcomes in asthma. Long-
term smoking in individuals with early stage COPD is characterized 
by prominent small airways dysfunction (SAD).12 In some aspects, 
patients with asthma who smoke may be considered to be a similar 
in phenotype to patients with asthma COPD overlap.13 Notably in 
smokers with normal spirometry, 76% have evidence of small air-
ways abnormality detected using impulse oscillometry (IOS) or mul-
tiple breath nitrogen washout.14
Assessment of SAD in the clinic may be done using impulse os-
cillometry (IOS) which is a simple to perform effort independent test 
using a loudspeaker source to superimpose sound waves of different 
frequencies on top of normal tidal breathing.15,16 The output of re-
spiratory impedance comprises an in phase component of resistance 
(R) and an out of phase component of reactance (X). The resistance 
at 5Hz (R5) and 20Hz (R20) represents the total and central airway 
resistance respectively; hence, the difference (R5-R20) is the het-
erogeneity of resistance in peripheral airways.17 The reactance at 
5Hz (X5) and area under the reactance curve (AX) reflects periph-
eral lung compliance. R5-R20 and AX have been shown to be more 
closely related to asthma control than spirometry in patients with 
persistent asthma.18,19
The role of triple therapy in asthma is well established in guide-
lines with long-acting muscarinic antagonists (LAMA) being rec-
ommended as add on to inhaled corticosteroid and long-acting 
beta-agonist (ICS/LABA).20 Once daily LAMA as tiotropium (TIO) 
added on to ICS/LABA in asthma has been shown to produce a 21% 
reduction in exacerbations and an improvement in trough FEV1 of 
between 88 and 111 mL.21 Pointedly, patients were required to be 
either lifelong non-smokers or a pack history fewer than 10 pack 
years along with no current smoking in the previous year. However, 
in that study, no measurement was made of small airways function.
The advent of single closed triple inhalers for COPD is well 
established,22 while clinical trials are ongoing in asthma. The 
TRIMARAN and TRIGGER studies in uncontrolled asthma compared 
the closed triple beclomethasone/formoterol/glycopyrroniumversus 
beclomethasone/ formoterol via pressurized metered dose inhaler 
(pMDI) twice daily showed a 12-15% reduction in exacerbations and 
a 57-73 mL difference in trough FEV1 as co-primary end-points.23 
This study also excluded current or ex-smokers with more than 10 
pack years.
In order to fill a gap in literature, we therefore elected to evalu-
ate in asthmatic smokers the effect of once daily ultra-long-acting 
bronchodilators as the LABA olodaterol (OLO) or the combination 
of olodaterol with the LAMA tiotropium (OLO/TIO), both delivered 
via the soft mist Respimat inhaler (Striverdi and Spiolto Respimat, 
Boerhinger Ingelhiem,Bracknell, UK), when added onto pre-exist-
ing ICS as HFA-beclomethasone dipropionate (BDP, Clenil Modulite 
pMDI, Chiesi, Manchester, UK). The rationale for choosing the 
Respimat device was that it was possible to deliver the OLO and 
OLO/TIO via the same device albeit in open label fashion. Hence, 
patients always took the same pMDI and Respimat devices for triple 
and dual therapy.
2  | PATIENTS AND METHODS
Patients with a known diagnosis of persistent asthma who were cur-
rent smokers were enrolled, age 18-65 years, taking at least 400 µg 
per day of ICS (as HFA-BDP Clenil equivalent dose). Participants 
with a history of COPD or ACO were excluded. Patients who had 
an asthma exacerbation requiring systemic corticosteroids within 
1 month of screening or requiring hospital admission within 3 months 
were also excluded.
Including screening, there were five visits in total (Figure 1). 
After initial screening, patients entered into a 2-4 week run-in period 
when LABA or LAMA were stopped and participant's ICS dose was 
rounded to equivalent reference ICS as HFA-BDP (Clenil Modulite 
pMDI). This dose of Clenil was then continued unchanged through-
out the study. Other concomitant non-bronchodilator second line 
controllers such as leukotriene receptor antagonists, theophylline or 
cromones were permitted to be continued throughout the study but 
were withheld for 72 hours prior to each visit. Patients were allowed 
SABA during the study but asked to withhold it at least 6 hours prior 
to any study visit.
After the run-in period, patients were then randomized in cross-
over fashion to receive open label treatment with either Olodaterol 
Respimat 2 puffs (5 µg) or Olodaterol/Tiotropium 2 puffs (5 µg/5 µg) 
once daily in the morning for 2-4 weeks as add on to Clenil. There 
was a 2- to 4-week washout period in between randomized treat-
ment arms when patients continued on Clenil. The 2- to 4-week pe-
riod was chosen to allow flexibility for patients for treatments and 
washout periods, given that 2 weeks are adequate to reach steady 
state for airway effects of olodaterol and tiotropium.
Measurements including IOS oscillometry (Jaeger Masterscreen 
IOS, Hoechberg, Germany), spirometry (Superspiro, Micromedical, 
Chatham UK) and ACQ were made at baseline after run-in and wash-
out (on Clenil) and after the first and last dose of each randomized 
treatment on either BDP/OLO or BDP/OLO/TIO. IOS and spirometry 
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were both measured at baseline before the first dose and at peak 
1 hour post first dose and then at trough and peak after chronic dos-
ing—that is trough being immediately prior to the last morning dose 
and peak being 1 hour post last dose. All visits were performed in the 
mornings (8 am-10 am).
Domiciliary diary data were collected for symptoms, peak flow 
and reliever use throughout the study.
Allergic status was defined as having at least one positive skin 
prick test to a panel of common aeroallergens (Diagenics Ltd, Milton 
Keynes, UK).
Informed consent was obtained from all patients, and ethical 
permission was obtained. The study was registered at clinicaltrials.
gov as NCT02682862 and was approved by the East of Scotland 
Regional Ethics Committee (reference: 15/ES/0032).
2.1 | Statistical analysis
The study was powered on R5 as the primary end-point. Sixteen pa-
tients were required to complete per protocol to achieve 90% power 
in order to detect a 30% difference for the comparison between ran-
domized treatments in R5 as change from baseline (ie OLO/TIO vs 
OLO), using a crossover design with alpha error of 0.05 (two tailed). 
The rationale was that R5 represents total airway resistance, such 
that if large airway resistance as R20 was unchanged, then the pri-
mary outcome would therefore reflect small airways—that is rather 
than powering on R5-R20 which is an artificial composite measure 
which encompasses two separate components of variance.
All data were first examined for normality and distribution. A 
comparison was made of respective baseline values after run-in and 
washout periods. Repeated measures analysis of variance (ANOVA) 
was carried out assessing for treatment and sequence effects, 
given the crossover design. The overall ANOVA was used to initially 
compare values for pooled baseline and each randomized treatment, 
where the overall ANOVA showed a significant overall difference a 
single paired t test was then applied to compare between random-
ized treatments, that is BDP/OLO/TIO versus BDP/OLO. In order to 
obviate possible confounding of the overall alpha error, no formal 
pairwise comparisons were made for each randomized treatment 
versus baseline. 95% CI for the mean difference between treatments 
was also derived. A P-value of <.05 (two tailed) was considered as 
being statistically significant. Statistical analysis was completed 
using IBM SPSS (version 22, IBM analytics, New York).
3  | RESULTS
Of seventeen patients randomized, sixteen current smokers with 
persistent asthma completed per protocol, 1 randomized patient was 
withdrawn due to failure to comply with protocol, and there were no 
other withdrawals post randomization (Figure 2). Participants had a 
mean age of 44 years, FEV1 of 84%, FEF25-75 of 47%, R5 of 158%, 
ACQ of 1.69, 20 pack years smoking history. The median dose of 
HFA-BDP during run-in was 800 µg/day. 12/16 patients had at least 
one positive skin prick test with a median of 2 (IQR 2-4). The median 
duration for treatment, run-in and washout periods was 3 weeks.
There were no differences in any outcomes comparing respective 
baseline values prior to treatment with OLO vs OLO/TIO (Table 1).
There were significant overall differences for IOS values after 
chronic dosing at trough comparing values at baseline and after ran-
domized treatments (Table 2) with OLO or OLO/TIO. However, we 
did not perform individual pairwise comparisons between each ran-
domized treatment vs baseline to obviate confounding the overall 
alpha error.
For the comparison between randomized treatments, after 
chronic dosing IOS outcomes at trough, except for R20, were 
F I G U R E  1   Flow chart for study visits. The median duration for treatments, run-in and washout periods was 3 weeks
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significantly improved with OLO/TIO compared to OLO (Table 2 and 
Figure 3). For the primary end-point of total airway resistance (as R5), 
the mean difference (95%CI) between OLO/TIO vs OLO was 0.06 ( 
0.015-0.10) kPa/l/s, for peripheral airways resistance (as R5-R20) 
0.03 (0.003-0.06) kPa/l/s, for peripheral lung reactance area (as AX) 
0.38 (0.08-0.68) kPa/l, for peripheral lung reactance at 5Hz (as X5) 
−0.03 (−0.05 - −0.01) kPa/l/s, and for resonant frequency (as Fres) 
2.28 ( 0.45-4.12) Hz. To estimate the minimal important difference 
in small airways response, we calculated from regression analysis the 
delta response for IOS outcomes between BDP/OLO/TIO vs BDP 
which corresponded to a change in ACQ of 0.5. This amounted to a 
41% difference in AX and a 37% difference in R5-R20.
After chronic dosing, FEF25-75 at trough was also better with 
OLO/TIO vs TIO: 0.93 (0.86 - 0.95) l/s, while FEV1 at trough was not 
different (Table 2). There was also a small but significant difference 
in trough FVC between treatments (Table 2).
There were no significant differences between radnomised treat-
ments in peak IOS and spirometry values after single or chronic dosing 
(Table 3).
There were significant (ANOVA P = .007) overall differences in 
mean ACQ values after chronic dosing comparing baseline (1.63) and 
randomized treatments: OLO (1.29) and OLO/TIO (1.03). However, 
there was no significant (P = .21) difference between treatments. 
The mean change from baseline in ACQ with OLO/TIO (0.59) but not 
OLO (0.33) exceeded the MCID of 0.5.
Domiciliary diary cards for symptoms, reliever use and peak flow 
showed significant overall differences between pooled baseline and 
randomized treatments, but there were no differences between ran-
domized treatments (Table 4).
4  | DISCUSSION
The results of the present study revealed significantly greater im-
provements at trough for all IOS outcomes except for R20 when 
comparing ICS/LABA/LAMA to ICS/LABA in the smoking asthma 
phenotype. Since R20 represents changes in large airways and 
was no different, the changes seen in R5 and R5-R20 are therefore 
F I G U R E  2   Consort diagram for 
participant flow





FEV1 (L) 2.42 (0.18) 2.39 (0.74) .54
FEF25-75 (L/s)
† 1.49 (0.17) 1.42 (0.18) .23
FVC (L) 3.49 (0.20) 3.49 (0.21) .98
R5 (kPa/l/s) 0.58 (0.03) 0.58 (0.04) .82
R20 (kPa/l/s) 0.42 (0.02) 0.41 (0.02) .55
R5-R20 (kPa/l/s) 0.16 (0.03) 0.17 (0.02) .32
AX (kPa/l) 1.64 (0.34) 1.98 (0.35) .19
fres (Hz) 18.70 (1.25) 20.79 (1.46) .13
X5 (kPa/l/s) -0.23 (0.03) -0.25 (0.03) .38
Note: Baseline values for lung function prior to each randomized 
treatment. Values are presented as mean (SEM), † Geometric mean 
(SEM).
P-value refers to comparison between baseline values.
Abbreviations: BDP, Beclomethasone dipropionate; OLO, Olodaterol; 
TIO, Tiotropium.
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indicative of effects occurring in small airways.17 Our findings sug-
gest that inhaled triple therapy was accompanied by attenuation of 
small airways dysfunction for both resistance and compliance. The 
observation of changes in IOS measurements at trough is clinically 
relevant since this coincides with the night-time period when the air-
ways are most vulnerable to bronchoconstrictor stimuli prior to the 
next morning dose. The lack of any difference between randomized 
treatments for peak IOS response can be explained by the effect 
on airway caliber with OLO being maximal in terms there being no 
further room for improvement with TIO. Presumably, the superior-
ity at trough but not peak for IOS outcomes with ICS/LABA/LAMA 
over ICS/LABA is due to a longer duration of action in small airways 
with TIO which is evident at the end of the 24 hours dosing interval 
despite there being no difference in FEV1.24 Whether or not such 
superiority for trough IOS effects with triple therapy translates into 
reduced exacerbations in current smokers warrants further study 
over the longer term.In patients with uncontrolled asthma who were 
not current smokers, the use of medium and high dose extrafine 
beclometasone/formoterol/glycopyrronium (as single triple) versus 
beclometasone/formoterol over 52 weeks resulted in a 57-73 mL 
improvement in trough FEV1 along with a 12%-15% reduction in ex-
acerbations and no difference in ACQ.23
Our results showed that FEF25-75 but not FEV1 was also sensi-
tive in detecting improved response at trough comparing randomized 
treatments. FEF25-75 is thought to reflect volume dependent closure 
in small airways.9 Hence, we took great care to ensure that patients 
always breathed out all the way to residual volume, along with close 
inspection of the expiratory flow volume loop with each measurement. 
In this regard, we have previously reported that abnormal values of 
FEF25-75 and R5-R20 are equally predictive of oral corticosteroid and 
salbutamol use over a 2-year period.25 There was also a small but sig-
nificant difference in FVC between treatments which could represent 
subtle changes in air trapping due to small airways disease, as has pre-
viously been shown on imaging with extrafine particle HFA-BDP.26
Pooled baseline BDP Post BDP/OLO Post BDP/OLO/TIO ANOVA
FEV1 (L) 2.40 (0.18) 2.53 (0.18) 2.60 (0.18) <0.001
FEF25-75 (L/s)
† 1.46 (0.17) 1.58 (0.18) 2.51 (0.17) ** <0.001
FVC (L) 3.49 (0.20) 3.59 (0.21) 3.69 (0.20)* <0.001
R5 (kPa/l/s) 0.58 (0.03) 0.56 (0.045) 0.51 (0.40)* 0.002
R20 (kPa/l/s) 0.42 (0.02) 0.41 (0.02) 0.39 (0.02) 0.047
R5-R20 (kPa/l/s) 0.17 (0.03) 0.15 (0.03) 0.12 (0.03)* 0.007
AX (kPa/l) 1.81 (0.32) 1.54 (0.40) 1.16 (0.34)* 0.004
fres (Hz) 19.75 (1.19) 18.40 (1.54) 16.11 (1.48)* 0.001
X5 (kPa/l/s) -0.24 (0.03) -0.21 (0.03) -0.19 (0.03)* 0.001
Note: Trough values for lung function after chronic dosing following treatment with BDP/OLO or 
BDP/OLO/TIO.
Values are presented as mean (SEM), † Geometric mean (SEM).
Repeated measures ANOVA P value for overall comparison between baseline and following 
randomized treatments.
Abbreviations: BDP, Beclomethasone dipropionate; OLO, Olodaterol; TIO, Tiotropium.
*Denotes significant difference (P < .05), **(P < .001) between for comparison between OLO vs 
OLO/TIO after chronic dosing at trough. 
TA B L E  2   Trough values after chronic 
dosing following randomised treatments
F I G U R E  3   Effects of randomized treatments on trough lung function measurements after chronic dosing with either olodaterol (OLO) 
or olodaterol/tiotropium (OLO/TIO) added to HFA-BDP (Clenil). P-values are depicted for overall repeated measures ANOVA comparing 
baseline vs randomized treatment and also for the comparison between randomized treatments at trough after chronic dosing—that is for 
BDP/OLO/TIO vs BDP/OLO. Values are shown as means and SEM
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It is also noteworthy that the change in ACQ from baseline 
exceeded the minimal clinical important difference of 0.527 in re-
sponse to ICS/LABA/LAMA but not ICS/LABA, although the differ-
ence between treatments was not significant per se. The effect of 
ICS/LABA/LAMA on ACQ may be clinically pertinent in the longer 
term as ACQ is known to be a strong predictor of future exacerba-
tions.28,29 Further studies will be required to confirm whether the 
use of single inhaler triple therapy results in reduction in long-term 
exacerbation risk.
Our results showed no significant difference between ran-
domised treatments in diary card recordings of domiciliary peak 
flow, reliever use or symptoms scores, in turn suggesting that these 
measurements are relatively disconnected from the observed ef-
fects on small airways dysfunction.
We appreciate that there are potential limitations to our 
study which warrant consideration. The OLO and OLO/TIO inhal-
ers were administered as open label. However, since both were 
delivered via the same Respimat device, we do not believe this 
would be an important confounder. One might also argue that the 
duration of treatment was relatively short at 2-4 weeks, although 
it was clearly sufficient to be able to detect differences in trough 
effects on IOS after chronic dosing. We gave both Respimat 
inhalers at the usual recommended dose of 2 puffs once daily, 
although we acknowledge that neither of these inhalers are li-
censed for asthma per se as add to ICS. We used the Respimat 
merely to allow us to have the same device for ICS containing 
dual and triple therapy and because a similar inhalation technique 
is required for Respimat and pMDI, to make it easier for patients 
to use. At the time of the study inception, it was not possible to 
deliver ICS/LABA and LAMA via the same device. It would now 
be feasible to compare single triple versus ICS/LABA inhalers 
via the same device such as Ellipta (Trelegy and Relvar Ellipta, 
GlaxoSmithKline, Uxbridge, UK) or pMDI (Trimbow and Fostair 
pMDI solution, Chiesi, Manchester, UK). The median daily dose 
of HFA-BDP as Clenil was 800ug; hence, it is possible that there 
may not have been such prominent effects of randomised treat-
ments on IOS had the dose been higher or perhaps if we had used 
an extrafine HFA-BDP formulation.30 Although we did not assess 





ANOVABDP/OLO BDP/OLO/TIO BDP/OLO BDP/OLO/TIO
FEV1 (L) 2.40 (0.18) 2.64 (0.19) 2.65 (0.20) <0.001 2.70 (0.19) 2.74 (0.18) <0.001
FEF25-75 (L/s)
† 1.46 (0.17) 1.79 (0.20) 1.78 (0.23) <0.001 1.82 (0.21) 1.85 (0.21) <0.001
FVC (L) 3.49 (0.20) 3.65 (0.21) 3.63 (0.21) <0.001 3.71 (0.21) 3.77 (0.20) <0.001
R5 (kPa/l/s) 0.58 (0.03) 0.44 (0.03) 0.43 (0.03) <0.001 0.45 (0.04) 0.44 (0.04) <0.001
R20 (kPa/l/s) 0.42 (0.02) 0.36 (0.02) 0.35 (0.02) <0.001 0.36 (0.02) 0.36 (0.02) <0.001
R5-R20 (kPa/l/s) 0.17 (0.03) 0.09 (0.02) 0.08 (0.02) <0.001 0.09 (0.02) 0.08 (0.02) <0.001
AX (kPa/l) 1.81 (0.32) 0.84 (0.23) 0.75 (0.21) <0.001 0.80 (0.23) 0.70 (0.22) <0.001
fres (Hz) 19.75 (1.19) 14.66 (1.17) 14.48 (1.15) <0.001 14.09 (1.27) 13.69 (1.19) <0.001
X5 (kPa/l/s) -0.24 (0.03) -0.17 (0.03) -0.15 (0.02) <0.001 -0.16 (0.02) -0.15 (0.02) <0.001
Note: Peak values post dose for lung function after single and chronic dosing.
Values are presented as mean (SEM), † Geometric mean (SEM).
Repeated measures ANOVA P-value for overall comparison between baseline and randomized treatments.
There were no significant differences between BDP/OLO/TIO vs BDP/OLO.
Abbreviations: BDP, Beclomethasone dipropionate; OLO, Olodaterol; TIO, Tiotropium.
BDP Post BDP/OLO Post BDP/OLO/TIO ANOVA
Symptoms am 0.71 (0.12) 0.51 (0.14) 0.39 (0.10) 0.012
Symptoms pm 0.63 (0.10) 0.31 (0.12) 0.27 (0.08) <0.001
Reliever am (puffs/day) 1.05 (0.20) 0.55 (0.17) 0.45 (0.15) 0.009
Reliever pm (puffs/day) 0.92 (0.20) 0.55 (0.15) 0.33 (0.09) 0.009
PEF am (L/min) 369 (26) 384 (29) 385 (28) 0.018
PEF pm (L/min) 388 (31) 408 (34) 420 (31) 0.002
Note: Domiciliary diary card values are presented as means (SEM).
Repeated measures ANOVA P-value for overall comparison between baseline and randomized 
treatments. There were no significant differences between BDP/OLO/TIO vs BDP/OLO.
Abbreviations: BDP, Beclomethasone dipropionate; OLO, Olodaterol; PEF, peak expiratory flow; 
TIO, Tiotropium.
TA B L E  4   Domiciliary daird card data 
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adherence to the separate BDP and OLO/TIO inhalers, we are 
confident that the observed chronic dosing improvements in IOS 
with OLO/TIO compared to HFA-BDP alone are in keeping with 
patients having taken most of the prescribed doses as instructed. 
Indeed correct inhaler technique was reinforced at each visit. We 
did not perform any other small airways assessments such as mul-
tiple breath nitrogen washout, whole body plethysmography or 
imaging.9 Further studies using these techniques might be helpful 
to validate our findings with triple therapy in the smoking asthma 
phenotype.
We have previously performed a study in mild to moderate 
non-smoking asthma patients where they took a either indacaterol 
or indacaterol/tiotropium once daily as add on to ICS.31 In that 
study, we observed significant improvements compared to baseline 
on ICS alone for R5, R5-20 and AX, but no differences between 
randomized treatments. However, the smoking patients in the pres-
ent study had worse asthma control as ACQ (0.72 vs 1.69) while 
R5% predicted values were similar (160% vs 158%). The better ef-
fects of LABA/LAMA occurring in asthmatic smokers are perhaps 
similar to what one might expect to see with an ACO phenotype, 
especially the response to LAMA.13 The improvements seen with 
LAMA in addition to ICS/LABA may reflect the accentuated cholin-
ergic bronchomotor tone which occurs such patients. One previous 
study compared the effects of adding in a single dose of TIO or 
placebo in nine smoking and nine non-smoking patients not all of 
whom were taking ICS/LABA. They found no significant difference 
in the acute response to TIO between groups in spirometry mea-
surements—pointedly, they did not perform either chronic dosing 
or measure small airways with IOS.32 We also duly acknowledge 
that smoking cessation strategies should be an integral part of the 
clinical management plan for asthmatics who smoke in addition to 
optimizing inhaler therapy.
In summary, we have shown that chronic dosing with triple ther-
apy comprising ICS/LABA/LAMA is superior to dual therapy with 
ICS/LABA for effects on trough small airway outcomes in asthma 
patients who smoke. Further studies are warranted in this pheno-
type to evaluate whether such effects on small airways function 
translate into a reduced exacerbation risk when using closed single 
triple inhalers.
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